Published in final edited form as:

ACS Comb Sci. 2011 September 12; 13(5): . doi:10.1021/co200027c.

Application of Sequential Cu(I)/Pd(0)-Catalysis to Solution-Phase Parallel Synthesis of Combinatorial Libraries of Dihydroindeno[1,2-c]isoquinolines

Sarvesh Kumar, Thomas O. Painter, Benoy K. Pal, Benjamin Neuenswander, and Helena C. Malinakova*

Department of Chemistry, The University of Kansas, 1251 Wescoe Hall Drive, Lawrence, Kansas 66045, and The University of Kansas Center of Excellence in Chemical Methodologies and Library Development, 2034 Becker Drive, Shankel Structural Biology Center, West Campus Lawrence, Kansas 66047-3761

Abstract

Parallel solution-phase synthesis of combinatorial libraries of dihydroindenoisoquinolines employing a sequential Cu(I)/Pd(0)-catalyzed multi-component coupling and annulation protocol was realized. The scope and limitations of the protocol with respect to the substitution pattern in the aryl ring of the indene core, as well as the *N*-substituent have been defined, revealing that the methodology is compatible with a wide-range of aliphatic linear, branched and ester functionalized *N*-substituents. Unexpectedly, the formation of regioisomers featuring a 1,2,3-contiguous substitution pattern in the aromatic ring of the indene core was observed. Three distinct combinatorial libraries with a total of 111 of members were synthesized, and 80 highly substituted dihydroindenoisoquinolines structurally related to known medicinal agents including some consisting of mixtures of two regioisomers were made available for biological activity testing.

Keywords

solution-phase parallel synthesis; combinatorial libraries of heterocycles; dihydroindenoisoquinolines; multi-component reactions; transition metal-catalyzed reactions

Introduction

Solution-phase parallel synthesis serves as a powerful tool for the preparation of large libraries of compounds needed for drug discovery.¹ In order to deliver libraries featuring structurally complex and chemically diverse chemotypes, new technically challenging synthetic protocols must be adapted to the parallel synthesis format.² Multi-component reactions, and particularly those catalyzed by transition metals³ are well suited for a rapid construction of diverse libraries. However, the application of transition metal-catalyzed reactions often utilizing sensitive organometallic reagents or reactive intermediates to parallel synthesis still presents a synthetic and technical challenge.²

Recently, we have reported a new methodology for the synthesis of indenoisoquinolines **IV** relying on a combination of Cu(I)-catalyzed three-component coupling followed by an

*To whom the correspondence should be addressed. Phone: 1-785-864-4743. Fax: 1-785-864-5396. hmalina@ku.edu.

Supporting Information. General experimental procedures, full characterization data for eighteen (18) compounds and copies of ¹H and ¹³C NMR spectra and HPLC traces for fully characterized compounds (18) and additional selected products. The material is available free of charge via the Internet at <http://pubs.acs.org>.

intramolecular Pd(0)-catalyzed annulation, and demonstrated its utility by the preparation of a series of indenoisoquinolines in a classical synthetic format (Figure 1).⁴ Mechanistically, the process involves an in situ formation of an acyliminium chloride from imines **I** and acyl chlorides **III**. The acyliminium intermediate is then attacked by an organocuprate generated from the vinyl stannane **II** and the Cu(I) catalyst yielding the amide product (Figure 1).⁵ In the second step, Pd(0) catalyst initiates an intramolecular Heck reaction followed by an electrophilic palladation of the aromatic ring, and the entire sequence is terminated by a reductive elimination that closes the five-membered ring⁴ (Figure 1).

Indenoisoquinolines **V** came into prominence in medicinal chemistry as prototypes of novel anticancer chemotherapeutic agents inspired by the structures of naturally occurring topoisomerase I inhibitors benzophenanthridine alkaloids, e.g fagaronine, and a natural product camptothecin believed to function as DNA intercalators (Figure 2).⁶ Dihydroindenoisoquinolines **VI** have been shown to exhibit potent cytotoxicity serving as prodrugs of indenoisoquinolines in cancer cells.⁷ In the context of those studies, the angularly substituted dihydroindenoisoquinoline **VII** was synthesized and found to be less cytotoxic but retained a moderate topoisomerase I inhibitory activity, apparently acting via a mechanism distinct from the DNA intercalation precluded by its non-planar structure.^{7a} This finding is a source of motivation for a broader survey of biological activities of angularly substituted indenoisoquinolines. Thus, the development of a viable solution-phase parallel synthetic methodology for the preparation of combinatorial libraries of novel indenoisoquinolines is essential to providing an efficient access to these valuable heterocyclic structures.

Herein, we describe the application of our sequential Cu(I)/Pd(0)-catalyzed multi-component coupling/annulation protocol to solution-phase parallel synthesis of medium-size combinatorial libraries of indenoisoquinolines **IV** (Figure 3). The method was successfully adapted for the parallel synthesis format, and the scope and limitations in the substitution patterns on the indenoisoquinoline cores have been surveyed. The ability to achieve a broad variation in the *N*-substituent in the imine building block was demonstrated for the first time. Our methodology delivers a highly modular approach to substituted indenoisoquinolines and serves as a useful alternative to the traditionally employed routes.⁸ Compounds prepared by this study have been made available for a broad array of biological screens.⁹

Results and Discussion

To assess the challenges of adapting our methodology to the solution-phase parallel library synthesis, we embarked on the preparation of a limited validation library of six indenoisoquinolines **6**{*I*-3, *I*, *I*-2}. The validation library featured two elements of diversity, including three aromatic aldehydes **1**{*I*-3} (*R*¹) and two aryl chlorides **5**{*I*-2} (*R*³) (Figure 4). In all cases *N*-benzylamine **2**{*I*} was used to prepare the corresponding imines **3**{*I*-3, *I*} (Scheme 1).

In the initial attempt at the validation library synthesis, the reactions were performed in SPE tubes at room temperature under argon atmosphere. No reaction was observed, presumably due to lower reactivity of the vinyl tin reagent at room temperature. Indeed reactions performed well at elevated temperatures (45 °C, 6 h) in glass tubes. Furthermore, higher quality of CuCl (99% purity), improved drying of the imines building blocks produced in bulk quantities, and the addition of molecular sieves were employed. Thus, the protocol for the validation library synthesis was modified. The preparation was performed in the Miniblock XT synthesizer (24 membered) fitted with glass vials and reflux condensers, and the reactions were run at 45 °C for 6 h with magnetic stirring. Both the reagent addition and

the reaction were carried out under closed dry argon atmosphere (for details see the Supporting Information).

Gratifyingly, this protocol afforded all six intended validation library members in good yields over the two synthetic steps and very respectable crude purities (38-78%). The final products reached the purity standard higher than 90% measured by HPLC (UV 214 nm) required for the samples to be acceptable for biological testing.¹⁰ Identities of the products **6** were confirmed by ¹H NMR analyses, and data for compounds **6**{*1,1,1-2*} were compared to data obtained for samples produced in the classical format.⁴ The relative stereochemistry in products **6** reported in this study was assigned in accordance with the analytical data secured in our prior work.⁴ As anticipated, both the C-1 and C-3 carbon in the 2-naphthyl substituted imine underwent the terminal carbon-carbon bond forming event, providing 1:1 mixtures of isomeric indenoisoquinolines **6**{*3,1,1-2*} as indicated by ¹H NMR analyses, showing two sets of signals for the benzylic protons in the *N*-Bn group (signals at 5.61 ppm, and at 4.81 ppm in the spectra for **6**{*3,1,1*}) and for the methine CHN protons, signals at 5.54 ppm and at 5.46 ppm in the spectra for **6**{*3,1,1*}). However, HPLC analyses did not achieve separation of the peaks for the regioisomers, only giving rise to unsymmetrical peaks in the HPLC chromatograms.

Satisfied with the results of the validation library synthesis, we proceeded to explore the scope of the parallel synthesis protocol with respect to the range of structural diversity that could be tolerated in the aldehyde component. A series of imines **3**{*1-13,1*} all derived from *N*-benzyl amine component **2**{*1*} was prepared (Figure 4). Electronically distinct substituents (-Cl, -OMe, -Me and -NMe₂) were placed at the *para* position (C-4) of the aldehydes, and components with a varied placement (*meta* and *para*) of electronically distinct substituents (-Cl, -OMe, -Me) were included. The substituents and substitution patterns in the aromatic rings were chosen based on the operational scheme for aromatic substitution suggested by Topliss in a study on the methods for designing the most potent medicinal agents in the series of compounds bearing aromatic rings.¹¹ Since electrophilic aromatic palladation reactions performed intermolecularly were shown to strongly favor the formation of the less sterically hindered regioisomers, failing to yield a contiguous 1,2,3-trisubstitution pattern,¹² we were reasoning that steric effects would disfavor the terminal palladation at the C-2 position of the *meta*-substituted aldehydes **1**{*7,9,10*}, and the formation of single regioisomers of the corresponding indenoisoquinolines was anticipated. The selection of aldehydes **1**{*12, 13*} was driven by the desire to incorporate additional heteroatoms into the indenoisoquinolines **6**. The diversity of the aryl chloride component was limited to three components **5**{*1-3*} representing electronically neutral, electron rich and electron deficient substrates. Conceivably, electron deficient aryl chlorides might favor the iminium salt formation, as well as the oxidative addition of the palladium(0) catalyst into the Csp²-Br bond in the second step of the cascade event. Through the entire project, ethoxycarbonyl-substituted vinyl stannane **4** was employed, reasoning that the ester group in the indenoisoquinolines would allow for subsequent elaboration into any number of desirable appendages.

The protocol developed for the preparation of the validation library was applied to the synthesis of Library I (39 members) without modification. The crude reaction mixtures obtained in the final step were analyzed by HPLC to establish the crude purity (UV 214 nm), and were subsequently submitted to preparative HPLC with mass-directed fractionation to produce the final samples, the purity of which was established by HPLC (UV 214 nm) (run 1, Table 2). To evaluate reproducibility of the protocol, the preparation of the Library I was repeated under identical conditions for the synthesis (run 2, Table 2). A minor difference in the purification conditions involved the use of neutral mobile phase for the run one (1) analysis and purification, and an alkaline pH 9.8 mobile phase for analysis and purification

of the run two (2). The yields, purities (HPLC, UV 214 nm) for both the runs one (1) and two (2) as well as final amount (mg) of material available in purity higher than 90% are given in Table 2. Furthermore, compound identities were confirmed by ^1H NMR analyses that were performed on 21 out of the 39 members **6**. Selected library members (6 members) were fully characterized (*vide infra*).

Data in Table 2 indicate that imines derived from 1-naphthyl, 3-furyl- and 2-indolyl carbaldehydes **1**{**6**}, **1**{**12**} and **1**{**13**} did not prove to be competent substrates for this methodology, giving heterocycles **6** in low yields, and purities, or failing to deliver the products at all. Intrigued by the unexpectedly low purities initially reported for indenoisoquinolines **6** derived from the *meta*-substituted imines **3**{**7,1**}, **3**{**9,1**} and **3**{**10,1**} (3-Cl, 3-OMe and 3-Me), we carefully examined the HPLC chromatograms, MS data and ^1H NMR analyses of the corresponding indenoisoquinolines **6**. In fact, the analytical data revealed that purified samples of indenoisoquinolines **6** formed from imines **3**{**7,1**}, **3**{**9,1**} and **3**{**10,1**} possessed both the regioisomeric indenoisoquinolines arising from substitution at either C-2 or C-6 carbons of the aromatic ring of the carbaldehydes in significant quantities (1:2 – 1:3).¹³ Thus, an unexpected example of an intramolecular electrophilic palladation providing the contiguous 1,2,3-trisubstitution pattern was uncovered.^{14,15} When integrations for both the partially resolved peaks of the regioisomeric indenoisoquinolines from the HPLC chromatograms were entered into the results in Table 2, the combined purities were found to be significantly higher than 90% for products **6**{**9-10,1,1-3**}, and 88% and 91% for products **6**{**7,1,1**} and **6**{**7,1,2**} respectively, bearing an electron-withdrawing Cl substituent. As expected (*vide infra*) indenoisoquinolines **6**{**3,1,1-3**} derived from 2-naphthyl carbaldehyde were produced as 1: 1 mixture of regioisomers that were not separated by HPLC.

Aldehydes bearing a hydrogen or an electron-donating substituent in the *para* position (15 entries) all afforded the corresponding indenoisoquinolines in good yields (20-40% over the two step sequence) and good purities (> 90%), regardless of the choice of the acyl chloride component. Indenoisoquinolines **6**{**8, 1, 1-3**} derived from 4-Me₂N-substituted carbaldehyde **1**{**8**} proved to be an intriguing exception, being isolated in good yields but only 80-86% purity by HPLC (UV 214 nm). The samples of indenoisoquinolines **6**{**8,1,1-3**} were repurified by flash column chromatography. However, the purity by HPLC (UV 214 nm) had not improved. It is possible that the presence of the amine group and the choice of pH of the elution phase for HPLC leads to a retention of an impurity, the nature of which could not be elucidated from ^1H and ^{13}C NMR analyses. As anticipated based on our prior work,⁵ electron deficient aldehydes **1**{**4**} and **1**{**7**} afforded the indenoisoquinoline products **6**{**4, 1, 1-3**} and **6**{**7, 1, 1-3**} in diminished yields lower than 30% (mostly 7-15%) and somewhat lower purities (88-94%).

The preparation of Library I allowed us to survey the scope of the aldehyde building block for the novel indenoisoquinoline synthesis in the parallel format, identifying three aldehydes (1-naphthyl, 3-furyl and 2-indolyl, a total of 9 entries from 39, 23%) as unsuitable for the protocol. An unexpected formation of regioisomers via electrophilic aromatic palladation from *meta*-substituted aromatic carbaldehydes was observed. We confirmed that electron deficient carbaldehydes gave rise to lower yields, still providing useful product quantities. After subtracting the nine (9) entries that employed aldehydes outside the scope of this protocol and combining both the regioisomers of the indenoisoquinolines to signify a “combined final purity”, the success rate within the remaining 30-membered suite of compounds, defined as obtaining more than 5 mg of the product with HPLC (UV 214 nm) purity higher than 90% was 77%.¹⁰ The seven (7) members considered as failed (from the 30-compound suite) include six compounds possessing a relatively high purities (84-88% HPLC, UV 214 nm) and including the three 4-Me₂N-substituted products **6**{**8,1,1-3**}

(84-86% HPLC purity) for which the contaminant could not be detected by ^1H and ^{13}C NMR spectroscopy.

Having defined the scope of the methodology with respect to the aldehyde building block **1**, we turned our attention to exploring for the first time the diversification of the amine building block **2**. Variations in the *N*-substituent present an opportunity to significantly modify the physical, chemical and biological properties of the resulting heterocycles.¹⁶ Thus we embarked on parallel synthesis of Library II (24 members). Previously, *N*-benzyl amine **2**{1} was employed exclusively in all our syntheses of indenoisoquinolines. For the construction of Library II, six amines **2**{2-7} including aliphatic amines with straight chains, branching in α -positions or an ester (-COOEt) group at either α - or in β -positions were combined with aldehydes **1**{2} and **1**{4} bearing an electron donating (OMe) or electron withdrawing (Cl) substituents in the *para* positions to afford imines substrates **3**{2,2-7} and **3**{4,2-7} (Figure 5). Aryl chlorides **5**{1-2} were chosen to complete the building block set for Library II (Figure 5).

The protocol for the synthesis and purification used in the preparation of Library I was applied to the preparation of Library II without modifications. The synthetic sequence is depicted in Scheme 2.

The purities of the final products were established by HPLC (UV 214 nm), and the identities of products **6** were confirmed by recording ^1H NMR spectra for 6 out of the total of 24 of library members (Table 3). Selected library members (5 members) were fully characterized (*vide infra*). Data in Table 3 confirm that a broad diversification in the *N*-substituent of indenoisoquinolines **6** can be realized. Indenoisoquinolines **6** were obtained in yields 29-45% over the two synthetic steps with three exceptions, predictably involving the electron deficient *para* chloro-substituted aldehyde **1**{4}. Imines **3**{2,6-7} and **3**{4,6-7} featuring the *N*-glycine and its homolog as the *N*-substituents proved to be the most challenging substrates, giving lower yields and purities of the corresponding indenoisoquinolines. Nevertheless, five (5) out of eight (8) total entries with these *N*-substituents afforded acceptable quantities and purities of the indenoisoquinolines **6** with the glycine or homoglycine *N*-substituents (entries 9-12 and 21-24 Table 3). Twenty library members were obtained in quantities higher than 5 mg (10-38 mg) and purities higher than 90% (HPLC, UV 214 nm) corresponding to 83% success rate for Library II preparation. A single diastereomer of each product was obtained. The relative stereochemistry at the C-5/C-6 ring juncture in the heterocycles **6**{2,2-7,1-2} and **6**{4,2-7,1-2} was assigned in analogy to the structures of indenoisoquinolines **6** bearing the *N*-benzyl substituent and an NOE study on product **6**{2,3,1} was also attempted.¹⁷

After evaluating the results from the Library I and Library II syntheses, building blocks for the preparation of Library III were selected, aiming to assess the performance of the parallel synthetic methodology in systems diversifying both the amine and aldehyde components. Building blocks that performed successfully in syntheses of Libraries I and II were chosen. Thus, electron neutral, electron rich and electron deficient as well as one *meta*-substituted aldehyde **1**{1,2,4,5,10 and 11} (Figure 4) were combined with four (4) amines **2**{2,4,5 and 7} (Figure 5) to deliver the corresponding imines **3** (Figure 6). Utilizing the imines **3** shown in Figure 6 and two (2) aryl chlorides **5**{1-2} a 48-membered Library III of indenoisoquinolines **6** was synthesized proceeding according to the synthetic sequence outlined in Scheme 3 and employing the previously established method for the synthesis and purification (Table 4).

To confirm the identities of the library members, ^1H NMR was recorded on 15 out the total of 48 library members, and seven (7) indenoisoquinolines were fully characterized (*vide*

infra). Representative structures of indenoisoquinolines **6** prepared in Library III are shown in Figure 7.

In agreement with our prior observations, the inspection of HPLC and ¹H NMR data for indenoisoquinolines arising from the *meta*-Me substituted aldehyde **1**{*10*} indicated the formation of significant quantities (2:3 to 1:2 ratios) of both the regioisomers featuring two distinct substitution patterns in the aromatic ring of the indene substructure (Figure 7).¹⁸

When the final purities of these library members were adjusted for considering the “combined” content of both the regioisomers, thirty seven (37) out of a total of 48 samples were obtained in purities higher than 90% (HPLC, UV 214 nm) and sufficient quantities. Out of the eleven (11) members that failed to fulfill these criteria, six (6) library members were obtained in good quantities and purities 81-89%. These results translate into a success rate of 77% for compounds with HPLC purities > 90%, and a success rate 89% for compounds with HPLC purities (>80%). As anticipated, lower yields (10-15%) in comparison to the yields of other members (20-30%) were achieved with the electron deficient *para*-chloro substituted aldehyde, and four (4) out of the eleven (11) library members that failed the 90% purity criteria employed the aldehyde **1**{*4*}. Furthermore, the two library members utilizing the challenging *N*-homoglycine substituent and the electron deficient aldehyde were among the members that failed the purity criteria giving products with only 72% and 84% purity by HPLC (UV 214 nm).

Conclusion

In conclusion, a new and efficient method for solution phase parallel synthesis of combinatorial libraries of dihydroindeno[1,2-*c*]isoquinolines relying on a sequence of Cu(I)-catalyzed three-component coupling and Pd(0)-catalyzed intramolecular annulation⁴ was developed. The scope and limitations of the protocol with respect to the substitution pattern in the aryl ring of the indene core, as well as the *N*-substituent have been defined, revealing that the methodology is compatible with a wide-range of aliphatic linear, branched and ester functionalized *N*-substituents. Unexpectedly, the formation of regioisomers possessing a 1,2,3-contiguous substitution pattern in the aromatic ring of the indene core via an intramolecular electrophilic palladation was observed. Since preparative HPLC purification methods that have not been specifically optimized for the separation of the regioisomers already achieved a partial separation, we conclude that preparation of pure individual regioisomers is feasible, and work towards this goal is ongoing. To date, three distinct combinatorial libraries were synthesized and delivered 80 compounds with novel highly substituted indenoisoquinoline structures (some consisting of mixtures of regioisomers) that are currently being evaluated in high-throughput screens for a wide range of biological activities.⁹

Experimental Procedures

General Procedure for the parallel synthesis of the libraries

24-Member MiniBlock XT synthesizer vials (17×100 mm) were charged with activated 3Å MS (2.0 g) and CuCl (99.0% purity, 3.4 mg, 0.034 mmol, 0.2 equiv) utilizing a solid dispenser. Reaction vials were flushed with dry argon for 5 min. The stock solutions of imines **3** (0.17 mmol, 1.5 mL, 1.0 equiv) and aryl chlorides **5** (0.22 mmol, 1.5 mL, 1.3 equiv) in acetonitrile were injected via a syringe into the reaction vials. The reaction mixtures were stirred at room temperature for 5 minutes under dry argon atmosphere followed by the addition of the stock solution of the vinyl stannane **4** (0.34 mmol, 1.5 mL, 2.0 equiv) in dichloromethane. The reaction vials were stirred at 45 °C for 6 hours under argon atmosphere on IKA stirring plates with a thermocouple inserted into the metal block.

The reaction mixtures were cooled to room temperature and diluted with ethyl acetate (1.0 mL) and saturated aqueous KF solution (1.0 mL) and stirred further at RT for 16 h. The reaction mixtures were filtered into reaction vials (17×100 mm) through PrepSep silica gel tubes (SPE) under air pressure and each tube was rinsed with ethyl acetate (2×3 mL) and the rinsed portions were eluted through SPE tubes. The eluents were evaporated using GeneVac EZ-2 evaporator.

Anhydrous sodium acetate (13.9 mg, 0.17 mmol, 1.0 equiv) and palladium acetate (1.9 mg, 0.0085 mmol, 0.05 equiv) were added by solid dispensers to reaction vials (17×100 mm) containing the crude products from the first step, the reaction vials were flushed with dry argon for 5 min at room temperature, and anhydrous DMF (1.8 mL) was added via a syringe. Reaction mixtures were heated under argon atmosphere at 120 °C for 24 hours on IKA plates with the thermocouple inserted into the metal block. The reaction mixtures were cooled to room temperature and diluted with ethyl acetate (2.0 mL) and filtered into barcoded CCT tubes through PrepSep silica gel columns (SPE) under air pressure. The reaction tubes were washed with ethyl acetate (2×2 mL) and filtered through SPE tubes as well. The solvents were removed on GeneVac HT4 evaporator. Crude products were subjected to HPLC (UV 214 nm) analysis followed by preparative HPLC purification with mass directed fractionation.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This work was supported by the National Institutes of Health Kansas University Chemical Methodologies and Library Development Center of Excellence (NIH0063950 P50). We thank our colleague Dr. Conrad Santini for his assistance with the organization of the library synthesis.

References

1. (a) Ivachtchenko AV, Golovina ES, Kadieva MG, Koryakova AG, Kovalenko SM, Mitkin OD, Okun IM, Ravnyeyko IM, Tkachenko SE, Zaremba OV. Solution Phase Parallel Synthesis of Substituted 3-Phenylsulfonyl-[1,2,3]triazolo[1,5-*a*]quinazolines: Selective Serotonin 5-HT₆ Receptor Antagonists. *J Comb Chem.* 2010; 12:445. [PubMed: 20349953] (b) Vooturi SK, Firestine SM. Solution-Phase Parallel Synthesis of Novel Membrane-Targeted Antibiotics. *J Comb Chem.* 2010; 12:151. [PubMed: 19928911] (c) Shih HW, Guo CW, Lo KH, Huang MY, Cheng WC. Solution-Phase Parallel Synthesis of Novel Spirooxazolinoisoxazolines. *J Comb Chem.* 2009; 11:281. [PubMed: 19199644] (d) Cafici L, Pirali T, Condorelli F, Del Grosso E, Massarotti A, Sorba G, Canonico PL, Tron GC, Genazzani AA. Solution-Phase Parallel Synthesis and Biological Evaluation of Combretatriazoles. *J Comb Chem.* 2008; 10:732. [PubMed: 18681482] (e) Taylor, JB.; Trigg, DJ., editors. *Comprehensive Medicinal Chemistry*. Elsevier; 2007.
2. (a) Zhang S, Chen J, Lykakis IN, Perchyonok VR. Streamlining organic free radical synthesis through modern molecular technology: from polymer supported synthesis to microreactors and beyond. *Curr Org Synth.* 2010; 7:117.(b) Evindar G, Batey RA. Parallel Synthesis of a Library of Benzoxazoles and Benzothiazoles Using Ligand-Accelerated Copper-Catalyzed Cyclizations of ortho-Halobenzanilides. *J Org Chem.* 2006; 71:1802. [PubMed: 16496964] (c) Mukade T, Dragoli DR, Ellman JA. Parallel Solution-Phase Asymmetric Synthesis of α -Branched Amines. *J Comb Chem.* 2003; 5:590.
3. (a) Dandapani S, Marcaurelle LA. Current strategies for diversity-oriented synthesis. *Curr Opp Chem Biol.* 2010; 14:362.(b) Yu X, Wu J. Synthesis of 1-(1H-Indol-3-yl)-1,2-dihydroisoquinolines via AgOTf-Catalyzed Three-Component Reactions of 2-Alkynylbenzaldehydes, Amines, and Indoles. *J Comb Chem.* 2010; 12:238. [PubMed: 20058905] (c) Li D, Duan S, Hu YJ. Three-

Component One-Pot Approach to Synthesize Benzopyrano[4,3-d]pyrimidines. *Comb Chem.* 2010; 12:895.

4. Jayanth TT, Zhang L, Johnson TS, Malinakova HC. Sequential Cu(I)/Pd(0)-catalyzed multicomponent coupling and annulation protocol for the synthesis of indenoisoquinolines. *Org Lett.* 2009; 11:815. [PubMed: 19159326]
5. Black DA, Arndtsen BA. Copper-Catalyzed Cross-Coupling of Imines, Acid Chlorides, and Organostannanes: A Multicomponent Synthesis of α -Substituted Amides. *J Org Chem.* 2005; 70:5133. [PubMed: 15960515]
6. (a) Tillequin F. Rutaceous alkaloids as models for the design of novel antitumor drugs. *Phytochem Rev.* 2007; 6:65. (b) Antony S, Agama KK, Miao ZH, Takagi K, Wright MH, Robles AI, Varticovski L, Nagarajan M, Morrell A, Cushman M, Pommier Y. Novel Indenoisoquinolines NSC 725776 and NSC 724998 Produce Persistent Topoisomerase I Cleavage Complexes and Overcome Multidrug Resistance. *Cancer Res.* 2007; 67:10397. [PubMed: 17974983] (c) Nagarajan M, Morrell A, Fort BC, Meckley MR, Antony S, Kohlhaugen G, Pommier Y, Cushman M. Synthesis and Anticancer Activity of Simplified Indenoisoquinoline Topoisomerase I Inhibitors Lacking Substituents on the Aromatic Rings. *J Med Chem.* 2004; 47:5651. [PubMed: 15509164] (d) Morrell A, Antony S, Kohlhaugen G, Pommier Y, Cushman M. Synthesis of nitrated indenoisoquinolines as topoisomerase I inhibitors. *Bioorg Med Chem Lett.* 2004; 14:3659. [PubMed: 15203138]
7. (a) Xiao X, Miao ZH, Antony S, Pommier Y, Cushman M. Dihydroindenoisoquinolines function as prodrugs of indenoisoquinolines. *Bioorg Med Chem Lett.* 2005; 15:2795. [PubMed: 15911256] (b) Jayaraman M, Fox BM, Hollingshead M, Kohlhaugen G, Pommier Y, Cushman M. Synthesis of New Dihydroindeno[1,2-c]isoquinoline and Indenoisoquinolinium Chloride Topoisomerase I Inhibitors Having High in Vivo Anticancer Activity in the Hollow Fiber Animal Model. *J Med Chem.* 2002; 45:242. [PubMed: 11754595]
8. (a) Mahmoud MR, EL-Shahawi MM, El-Bordany EAA, Abu EA, Fatma SM. Synthesis of Novel Indeno[1,2-c]isoquinoline Derivatives. *Synth Commun.* 2010; 40:666. (b) Van HTM, Le QM, Lee KY, Lee ES, Kwon Y, Kim TS, Le TN, Lee SH, Cho WJ. Convenient synthesis of indeno[1,2-c]isoquinolines as constrained forms of 3-arylisoquinolines and docking study of a topoisomerase I inhibitor into DNA-topoisomerase I complex. *Bioorg Med Chem Lett.* 2007; 17:5763. [PubMed: 17827007] (c) Morrell A, Placzek M, Parmley S, Grella B, Antony S, Pommier Y, Cushman M. Optimization of the Indenone Ring of Indenoisoquinoline Topoisomerase I Inhibitors. *J Med Chem.* 2007; 50:4388. [PubMed: 17676830]
9. Evaluation of the biological activity of the submitted compounds in high-throughput screens is currently underway, and results will become available via PubChem (<http://www.ncbi.nlm.nih.gov/pccompound>).
10. The KU-CMLD is required, under the terms of its grant, to adhere to these standards (HPLC assay > 90% (UV 214 nm), 5 mg minimum mass) for submission of compounds to the Molecular Libraries and Small Molecule Repository (MLSMR). KU biological collaborators obtain the identical compounds directly from CMLD.
11. Topliss JG. Utilization of operational schemes for analog synthesis in drug design. *J Med Chem.* 1972; 15:1006. [PubMed: 5069767]
12. (a) Stuart DR, Villemure E, Fagnou K. Elements of Regiocontrol in Palladium-Catalyzed Oxidative Arene Cross-Coupling. *J Am Chem Soc.* 2007; 129:12072. [PubMed: 17880083] (b) Hull KL, Sanford MS. Catalytic and highly regioselective cross-coupling of aromatic C-H substrates. *J Am Chem Soc.* 2007; 129:11904. [PubMed: 17845047]
13. ¹H NMR data for compound **6** {9,1,1} featured signals at 6.99 ppm (t, $J = 7.9$ Hz, 0.24 H) indicating the presence of the regioisomer with a contiguously substituted aromatic ring, and at 6.22 ppm (d, $J = 1.7$ Hz, 0.74 H) corresponding to the isomer with 1,2,4-substituted aromatic ring. ¹H NMR data for compound **6** {10,1,1} featured signals at 7.01 ppm (t, $J = 7.5$ Hz, 0.45 H) indicating the presence of the regioisomer with a contiguously substituted aromatic ring, and at 6.70 ppm (s, 0.55 H) corresponding to the isomer with 1,2,4-substituted aromatic ring.
14. For an example of an *intramolecular* electrophilic palladation favoring the formation of a contiguously trisubstituted aromatic ring, see: Ohno H, Iuchi M, Fujii N, Tanaka T. Zipper-Mode Double C-H Activation: Palladium-Catalyzed Direct Construction of Highly-Fused Heterocyclic Systems. *Org Lett.* 2007; 9:4813. [PubMed: 17924639] The presence of heteroatoms is known to

facilitate palladation in the *ortho* position: Harrowven DC, Woodcock T, Howes PD. Total synthesis of caviularin and riccardin C: Addressing the synthesis of an arene that adopts a boat configuration. *Angew Chem Int Ed*. 2005; 44:3899. Torres JC, Pinto AC, Garden SJ. Application of a catalytic palladium biaryl synthesis reaction, via C-H functionalization, to the total synthesis of Amaryllidaceae alkaloids. *Tetrahedron*. 2004; 60:9889. Hennings DD, Iwasa S, Rawal VH. Anion-Accelerated Palladium-Catalyzed Intramolecular Coupling of Phenols with Aryl Halides. *J Org Chem*. 1997; 62:2. [PubMed: 11671356]

15. For an example of an *intramolecular* electrophilic palladation yielding a contiguously tetrasubstituted aromatic ring via the only available regiochemical pathway, see: Sreenivas DK, Nagarajan R. Palladium-mediated intramolecular o-arylation: a simple route for the synthesis of quino[2,3-c] and quino[3,2-b]carbazoles. *Tetrahedron*. 2010; 66:9650.
16. Ahn G, Lansiaux A, Goossens JF, Bailly C, Baldeyrou B, Schifano-Faux N, Grandclaude P, Couture A, Ryckebush A. Indeno[1,2-c]isoquinolin-5,11-diones conjugated to amino acids: Synthesis, cytotoxicity, DNA interaction, and topoisomerase II inhibition properties. *Bioorg Med Chem*. 2010; 18:8119. [PubMed: 20961767]
17. The NOE data recorded for the indenoisoquinoline **6**{2,3,1} were consistent with the proposed structure, but were inconclusive in terms of assigning the relative stereochemistry. Efforts to obtain single crystals of several indenoisoquinolines **6** with diverse *N*-groups are in progress, but so far did not afford satisfactory results.
18. ¹H NMR spectra recorded for compound **6**{10,5,2} (no resolution of regioisomers was indicated by HPLC chromatogram) indicated the presence of two regioisomers in approximately 1 : 1 ratio, revealed by the signals at 6.94 ppm (s, 0.5 H); 5.33 (s, 0.5 H), 5.32 (s, 0.5 H).

Figure 1.
Synthetic strategy for the preparation of indenoisoquinolines

Figure 2.
Naturally occurring and synthetic cytotoxic topoisomerase I inhibitors

Figure 3.
Libraries of indenoisoquinolines synthesized by our methodology

Figure 4.
Building blocks for the validation library and Library I

Figure 5.
Building blocks for Library II

Figure 6.
Building blocks for Library III

Figure 7.
Examples of indenoisoquinolines prepared in Library III

Scheme 1. Synthetic scheme for the validation library and Library I synthesis

Scheme 2. Synthesis of Library II

Scheme 3. Synthesis of Library III

Table 1

Results of the validation library synthesis

entry	compd	R ¹	R ³	yield ^a (%)	purity crude ^b (%)	purity final ^b (%)	HRMS ^c
1	6{1,1,1}	H	5-H	42	67	97	398.1755 (398.1756)
2	6{1,1,2}	H	5-OMe	48	68	100	428.1859 (428.1861)
3	6{2,1,1}	4-MeO	5-H	50	64	100	428.1862 (428.1861)
4	6{2,1,2}	4-MeO	5-OMe	42	38	100	458.1963 (458.1967)
5	6{3,1,1}	2-naphthyl	5-H	71	78(1:1) ^d	92(1:1) ^d	448.1906 (448.1912)
6	6{3,1,2}	2-naphthyl	5-OMe	57	70 (1:1) ^d	92(1:1) ^d	478.2009 (478.2018)

^a Isolated yield calculated for the entire two-step sequence.

^b UV purity determined at 214 nm.

^c The HRMS data for the M + 1 molecular ion of the compound **6** detected in the corresponding product. The calculated HRMS data for the M + 1 molecular ion are given in parentheses.

^d Ratio of the regioisomers established by ¹H NMR.

Table 2

Results of library I synthesis

entr	compd	R ¹	R ³	yield ^a (%) run 1 ^f	purity ^b (%) run 1 ^f	yield ^a (%) run 2	purity ^b (%) run 2	amt (mg) ^c	pass/ fail ^d	HRMS ^e
1	6{1,1,1}	H	5-H	31 (42)	97 (97)	28	99	68	+	398.1752 (398.1756)
2	6{1,1,2}	H	5-OMe	2 (48)	94 (100)	31	98	59	+	428.1859 (428.1861)
3	6{1,1,3}	H	4,5-F ₂	16	92	14	86	12	+	434.1556 (434.1567)
4	6{2,1,1}	4-MeO	5-H	42 (50)	99 (100)	25	95	85	+	428.1875 (428.1861)
5	6{2,1,2}	4-MeO	5-OMe	4 (42)	97 (100)	30	99	60	+	458.1963 (458.1967)
6	6{2,1,3}	4-MeO	4,5-F ₂	30	93	33	93	50	+	464.1671 (464.1673)
7	6{3,1,1}	2-naphthyl	5-H	x (71)	x (92)	42	97(1 : 1) ^g	86	+	448.1906 (448.1912)
8	6{3,1,2}	2-naphthyl	5-OMe	6 (57)	85 (92)	57	97(1 : 1) ^g	97	+	478.2009 (478.2018)
9	6{3,1,3}	2-naphthyl	4,5-F ₂	32	85	33	73(1 : 1) ^g	0	-	484.1700 (484.1724)
10	6{4,1,1}	4-Cl	5-H	28	94	29	86	20	+	432.1356 (432.1366)
11	6{4,1,2}	4-Cl	5-OMe	5	70	24	94	22	+	462.1464 (462.1472)
12	6{4,1,3}	4-Cl	4,5-F ₂	7	88	x	x	0	-	468.1163 (468.1178)
13	6{5,1,1}	4-Me	5-H	35	98	36	97	50	+	412.1895 (412.1912)
14	6{5,1,2}	4-Me	5-OMe	4	94	38	96	32	+	442.2014 (442.2018)
15	6{5,1,3}	4-Me	4,5-F ₂	35	98	22	93	43	+	448.1711 (448.1724)
16	6{6,1,1}	1-naphthyl	5-H	13	95	7	95	15	EX ^h	448.1903 (448.1912)
17	6{6,1,2}	1-naphthyl	5-OMe	x	x	15	88	0	EX ^h	478.2010 (478.2018)
18	6{6,1,3}	1-naphthyl	4,5-F ₂	9	64	x	x	0	EX ^h	484.1716 (484.1724)
19	6{7,1,1}	3-Cl	5-H	20	37 ^g	12	29 ^g	0	-	432.1359 (432.1366)
					46		59

entr	compd	R ¹	R ³	yield ^a (%) run 1 ^f	purity ^b (%) run 1 ^f	yield ^a (%) run 2	purity ^b (%) run 2	amt (mg) ^c	pass/ fail ^d	HRMS ^e

20	6{7,1,2}	3-Cl	5-OMe	19	61 ^g	15	46 ^g	15	+	462.1468 (462.1472)
					30		34			
21	6{7,1,3}	3-Cl	4,5-F ₂	x	x	10	13	0	-	468.1167 (468.1178)
22	6{8,1,1}	4-Me ₂ N	5-H	31	80	32	86	0	-	441.2177 (441.2178)
23	6{8,1,2}	4-Me ₂ N	5-OMe	14	80	26	84	0	-	471.2280 (471.2283)
24	6{8,1,3}	4-Me ₂ N	4,5-F ₂	14	76	17	85	0	-	477.1980 (477.1989)
25	6{9,1,1}	3-OMe	5-H	29	72 ^g	34	63 ^g	50	+	428.1859 (428.1861)
					27		29			
26	6{9,1,2}	3-OMe	5-OMe	36	66	30	62 ^g	52	+	458.1963 (458.1967)
					33 ^g		31			
27	6{9,1,3}	3-OMe	4,5-F ₂	24	65 ^g	21	21 ^g	35	+	464.1665 (464.1673)
					28		66			
28	6{10,1,1}	3-Me	5-H	43	66 ^g	33	63 ^g	53	+	412.1916 (412.1912)
					31		32			
29	6{10,1,2}	3-Me	5-OMe	41	62 ^g	36	67 ^g	57	+	442.2019 (442.2018)
					35		27 ^g			
30	6{10,1,3}	3-Me	4,5-F ₂	28	63 ^g	31	74	45	+	448.1712 (448.1724)
					34					
31	6{11,1,1}	3,4,5-(OMe) ₃	5-H	37	91	39	93	62	+	488.2066 (488.2073)
32	6{11,1,2}	3,4,5-(OMe) ₃	5-OMe	41	93	34	92	66	+	518.2188 (518.2178)
33	6{11,1,3}	3,4,5-(OMe) ₃	4,5-F ₂	45	97	9	82	40	+	524.1886 (524.1884)
34	6{12,1,1}	3-furyl	5-H	24	74	19	69	0	EX ^h	388.1539 (388.1548)

entr	compd	R ¹	R ³	yield ^a (%) run 1 ^f	purity ^b (%) run 1 ^f	yield ^a (%) run 2	purity ^b (%) run 2	amt (mg) ^c	pass/fail ^d	HRMS ^e
35	6{12,1,2}	3-furyl	5-OMe	15	75	17	75	0	EX ^h	418.1649 (418.1654)
36	6{12,1,3}	3-furyl	4,5-F ₂	27	75	16	87	0	EX ^h	424.1354 (418.1360)
37	6{13,1,1}	2-indolyl	5-H	x	x	x	x	0	EX ^h	
38	6{13,1,2}	2-indolyl	5-OMe	x	x	x	x	0	EX ^h	
39	6{13,1,3}	2-indolyl	4,5-F ₂	x	x	x	x	0	EX ^h	

^a Isolated yield after HPLC purification calculated for the entire two-step sequence.

^b UV purity determined at 214 nm.

^c Amount of the sample that is available in UV purity > 90% (in mg).

^d Pass rating signified as (+) denotes a library member that was produced in quantity of 5 mg or higher, and higher than 90% UV purity in at least one of the two runs. Fail rating signified by (-) denotes a library member that did not fulfill these criteria both in run 1 and run 2.

^e The HRMS data for the M + 1 molecular ion of the compound 6 detected in the corresponding product. The calculated HRMS data for the M + 1 molecular ion are given in parentheses.

^f Results from the validation library run are indicated in parentheses for comparison.

^g Ratio of the regioisomeric products shown on the two lines (established from HPLC chromatograms) or in parentheses (established by ¹H NMR).

^h EX = excluded, building blocks were found to be outside the scope of the methodology, data was not included into the final evaluation. x = failed to yield any product.

Table 3

Results from Library II synthesis

6{2,2-7,1-2} 6{4,2-7,1-2}										
entry	compd	R ¹	R ²	R ³	yield ^a (%)	purity ^b (%)	amt (mg) ^c	pass/fail ^d	HRMS ^e	
1	6{4,2,1}	4-Cl	Me	H	37	94	22	+	356.1049 (356.1053)	
2	6{2,2,1}	4-OMe	Me	H	33	100	20	+	352.1577 (352.1548)	
3	6{4,3,1}	4-Cl	<i>n</i> -C ₃ H ₁₁	H	17	100	12	+	412.1666 (412.1679)	
4	6{2,3,1}	4-OMe	<i>n</i> -C ₃ H ₁₁	H	45	97	31	+	408.2171 (408.2174)	
5	6{4,4,1}	4-Cl	<i>i</i> -C ₃ H ₇	H	20	100	13	+	384.1375 (384.1366)	
6	6{2,4,1}	4-OMe	<i>i</i> -C ₃ H ₇	H	31	97	20	+	380.1885 (380.1861)	
7	6{4,5,1}	4-Cl	C ₆ H ₁₁ cyclohexyl	H	20	100	14	+	424.1671 (424.1679)	
8	6{2,5,1}	4-OMe	C ₆ H ₁₁ cyclohexyl	H	39	93	28	+	420.2175 (420.2174)	
9	6{4,6,1}	4-Cl	CH ₂ COOMe	H	10	98	7	+	414.1122 (414.1108)	
10	6{2,6,1}	4-OMe	CH ₂ COOMe	H	17	98	12	+	410.1606 (410.1603)	
11	6{4,7,1}	4-Cl	(CH ₂) ₂ COOMe	H	20	76	14	-	428.1270 (428.1264)	
12	6{2,7,1}	4-OMe	(CH ₂) ₂ COOMe	H	41	95	30	+	424.1781 (424.1760)	
13	6{4,2,2}	4-Cl	Me	OMe	41	98	27	+	386.1188 (386.1159)	
14	6{2,2,2}	4-OMe	Me	OMe	29	100	19	+	382.1664 (382.1654)	
15	6{4,3,2}	4-Cl	<i>n</i> -C ₃ H ₁₁	OMe	37	96	28	+	442.1798 (442.1785)	
16	6{2,3,2}	4-OMe	<i>n</i> -C ₃ H ₁₁	OMe	29	94	21	+	438.2293 (438.2280)	
17	6{4,4,2}	4-Cl	<i>i</i> -C ₃ H ₇	OMe	x	x	x	-

6{2,2-7,1-2}

6{4,2-7,1-2}

entry	compd	R ¹	R ²	R ³	yield ^a (%)	purity ^b (%)	amt (mg) ^c	pass/fail ^d	HRMS ^e
18	6{2,4,2}	4-OMe	<i>i</i> -C ₃ H ₇	OMe	35	99	25	+	410.1978 (410.1967)
19	6{4,5,2}	4-Cl	C ₆ H ₁₁ cyclohexyl	OMe	27	96	21	+	454.1773 (454.1785)
20	6{2,5,2}	4-OMe	C ₆ H ₁₁ cyclohexyl	OMe	31	92	24	+	450.2276 (450.2280)
21	6{4,6,2}	4-Cl	CH ₂ COOMe	OMe	6	17	4	-	444.1211 (444.1213)
22	6{2,6,2}	4-OMe	CH ₂ COOMe	OMe	16	98	12	+	440.1694 (440.1709)
23	6{4,7,2}	4-Cl	(CH ₂) ₂ COOMe	OMe	20	84	15	-	458.1363 (458.1370)
24	6{2,7,2}	4-OMe	(CH ₂) ₂ COOMe	OMe	45	94	38	+	454.1848 (454.1865)

^a Isolated yield after HPLC purification calculated for the entire two-step sequence.

^b UV purity determined at 214 nm.

^c Amount of the sample that is available in UV purity > 90% (in mg).

^d Pass rating signified as (+) denotes a library member that was produced in quantity of 5 mg or higher, and higher than 90% UV purity. Fail rating signified by (-) denotes a library member that did not fulfill these criteria.

^e The HRMS data for the M + 1 molecular ion of the compound **6** detected in the corresponding product. The calculated HRMS data for the M + 1 molecular ion are given in parentheses. x = failed to yield any product.

Table 4

Results from Library III synthesis

6

(1,2,4,5,10 and 11; 2,4,5 and 7; 1-2)

6

(10; 2,4,5 and 7; 1-2)

entry	compd	R ¹	R ²	R ³	yield ^a (%)	purity ^b (%)	amt (mg) ^c	pass/fail ^d	HRMS ^e
1	6{1,2,1}	H	Me	H	x	x	0	-	-
2	6{1,2,2}	H	Me	OMe	32	100	19	+	352.1553 (352.1548)
3	6{2,2,1}	4-OMe	Me	H	27	100	16	+	352.1550 (352.1548)
4	6{2,2,2}	4-OMe	Me	OMe	x	13	1	-	382.1650 (382.1654)
5	6{4,2,1}	4-Cl	Me	H	26	99	16	+	356.1058 (356.1053)
6	6{4,2,2}	4-Cl	Me	OMe	31	87	21	-	386.1170 (386.1159)
7	6{5,2,1}	4-Me	Me	H	27	100	16	+	336.1605 (336.1599)
8	6{5,2,2}	4-Me	Me	OMe	31	99	19	+	366.1724 (366.1705)
9	6{10,2,1}	3-Me	Me	H	40	58 ^f	17	+	336.1607 (336.1599)
						42			
10	6{10,2,2}	3-Me	Me	OMe	30	56 ^f	19	+	366.1711 (366.1705)
						43			
11	6{11,2,1}	3,4,5-(OMe) ₃	Me	H	27	95	19	+	412.1763 (412.1760)
12	6{11,2,2}	3,4,5-(OMe) ₃	Me	OMe	33	97	25	+	442.1859 (442.1865)
13	6{1,4,1}	H	<i>i</i> -Pr	H	16	94	9	+	350.1754 (350.1756)
14	6{1,4,2}	H	<i>i</i> -Pr	OMe	22	98	14	+	380.1859 (380.1861)
15	6{2,4,1}	4-OMe	<i>i</i> -Pr	H	16	99	10	+	380.1867 (380.1861)
16	6{2,4,2}	4-OMe	<i>i</i> -Pr	OMe	23	96	16	+	410.1967 (410.1967)
17	6{4,4,1}	4-Cl	<i>i</i> -Pr	H	10	100	7	+	384.1349 (384.1366)
18	6{4,4,2}	4-Cl	<i>i</i> -Pr	OMe	15	89	11	-	414.1475 (414.1472)

<div> <p>6</p> <p>{1,2,4,5,10 and 11; 2,4,5 and 7; 1-2}</p> <p>6(10; 2,4,5 and 7; 1-2)</p> </div>									
entry	compd	R ¹	R ²	R ³	yield ^a (%)	purity ^b (%)	amt (mg) ^c	pass/fail ^d	HRMS ^e
19	6 {5,4,1}	4-Me	<i>i</i> -Pr	H	14	99	8	+	364.1920 (364.1912)
20	6 {5,4,2}	4-Me	<i>i</i> -Pr	OMe	27	78	18	-	394.2017 (394.2018)
21	6 {10,4,1}	3-Me	<i>i</i> -Pr	H	11	38 ^f	7	+	364.1914 (364.1912)
						58			
22	6 {10,4,2}	3-Me	<i>i</i> -Pr	OMe	26	61 ^f	17	+	394.2023 (394.2018)
						33			
23	6 {1,1,4,1}	3,4,5-(OMe) ₃	<i>i</i> -Pr	H	23	95	17	+	440.2079 (440.2073)
24	6 {1,1,4,2}	3,4,5-(OMe) ₃	<i>i</i> -Pr	OMe	21	96	17	+	470.2180 (470.2178)
25	6 {1,5,1}	H	cyclohexyl	H	23	89	15	+	390.2076 (390.2069)
26	6 {1,5,2}	H	cyclohexyl	OMe	24	94	17	+	420.2174 (420.2174)
27	6 {2,5,1}	4-OMe	cyclohexyl	H	25	81	18	-	420.2183 (420.2174)
28	6 {2,5,2}	4-OMe	cyclohexyl	OMe	23	86	18	-	450.2276 (450.2280)
29	6 {4,5,1}	4-Cl	cyclohexyl	H	15	96	11	+	424.1680 (424.1679)
30	6 {4,5,2}	4-Cl	cyclohexyl	OMe	7	98	5	+	454.1777 (454.1785)
31	6 {5,5,1}	4-Me	cyclohexyl	H	17	97	12	+	404.2233 (404.2225)
32	6 {5,5,2}	4-Me	cyclohexyl	OMe	28	91	20	+	434.2333 (434.2331)
33	6 {10,5,1}	3-Me	cyclohexyl	H	21	95 ^g	15	+	404.2238 (404.2225)
34	6 {10,5,2}	3-Me	cyclohexyl	OMe	26	91 ^g	19	+	434.2337 (434.2331)
35	6 {1,1,5,1}	3,4,5-(OMe) ₃	cyclohexyl	H	14	89	12	-	480.2370 (480.2386)
36	6 {1,1,5,2}	3,4,5-(OMe) ₃	cyclohexyl	OMe	29	97	25	+	510.2476 (510.2491)
37	6 {1,7,1}	H	(CH ₂) ₂ COOMe	H	14	96	9	+	394.1669 (394.1654)
38	6 {1,7,2}	H	(CH ₂) ₂ COOMe	OMe	20	94	15	+	424.1760 (424.1760)

<div> </div> <div> $\{1,2,4,5,10 \text{ and } 11; 2,4,5 \text{ and } 7; 1-2\}$ </div> <div> $\{10; 2,4,5 \text{ and } 7; 1-2\}$ </div> <div> $\{10; 2,4,5 \text{ and } 7; 1-2\}$ </div>									
entry	compd	R ¹	R ²	R ³	yield ^d (%)	purity ^b (%)	amt (mg) ^c	pass/fail ^d	HRMS ^e
39	6 {2,7,1}	4-OMe	(CH ₂) ₂ COOMe	H	22	97	16	+	424.1776 (424.1760)
40	6 {2,7,2}	4-OMe	(CH ₂) ₂ COOMe	OMe	x	x	0	-	-
41	6 {4,7,1}	4-Cl	(CH ₂) ₂ COOMe	H	13	72	10	-	428.1279 (428.1264)
42	6 {4,7,2}	4-Cl	(CH ₂) ₂ COOMe	OMe	21	84	17	-	458.1358 (458.1370)
43	6 {5,7,1}	4-Me	(CH ₂) ₂ COOMe	H	28	93	20	+	408.1812 (408.1810)
44	6 {5,7,2}	4-Me	(CH ₂) ₂ COOMe	OMe	26	98	19	+	438.1903 (438.1916)
45	6 {10,7,1}	3-Me	(CH ₂) ₂ COOMe	H	25	53 ^f	18	+	408.1820 (408.1810)
						37			
46	6 {10,7,2}	3-Me	(CH ₂) ₂ COOMe	OMe	22	58	16	+	438.1907 (438.1916)
						37 ^f			
47	6 {11,7,1}	3,4,5-(OMe) ₃	(CH ₂) ₂ COOMe	H	28	96	23	+	484.1965 (484.1971)
48	6 {11,7,2}	3,4,5-(OMe) ₃	(CH ₂) ₂ COOMe	OMe	32	95	28	+	514.2053 (514.2077)

^aIsolated yield after HPLC purification calculated for the entire two-step sequence.

^bUV purity determined at 214 nm.

^cAmount of the sample that is available in UV purity > 90% (in mg).

^dPass rating signified as (+) denotes a library member that was produced in quantity of 5 mg or higher, and higher than 90% UV purity. Fail rating signified by (-) denotes a library member that did not fulfill these criteria.

^eThe HRMS data for the M + 1 molecular ion of the compound **6** detected in the corresponding product. The calculated HRMS data for the M + 1 molecular ion are given in parentheses.

^fRatio of the regioisomeric products established from the HPLC chromatogram is shown on the two lines.

^gThe peaks for the regioisomers were not resolved by HPLC, the presence of regioisomers was detected by ¹H NMR. x = failed to yield any product.